We do not yet have clear answers on: Long-term safety Optimal dosing strategies Metabolic interactions Effects on weight loss outcomes Some patients who stop GLP-1 treatment may see lost weight return over time
Once intact bacteria and other antigenic substances cross the intestinal wall, they encounter numerous immune cells that react to these substances, leading to inflammation
They were at a loss, too
Currently available GLP-1 receptor agonists include shorter-acting formulations such as exenatide (administered twice daily), daily options like liraglutide, and longer-acting agents like semaglutide and dulaglutide (weekly injections)
For example, immuno-oncology drugs, in the form of programmed cell death protein-1 (PD-1) antagonists, have a slower growth rate, with projections of a CAGR of 4.7% and a market size of $51 billion in 2029, nearly half of the GLP-1 agonist market ( see Figure 1) ,according to estimates from GlobalData